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In this paper, the rationale for the nonpharma-
cologic treatment of hypertension will be presented. A
decision-making matrix for implementing these strate-
gies, the practical issues concerning implementation,
the specific therapeutic techniques, and a comprehen-
sive treatment programme which addresses the entire
cardiovascular risk profile will also be presented.
Since a variety of health professionals are in-
volved in nonpharmacologic treatment modalities, the
term “clinician” is used generically to designate those
providing care.
1. DEFINITION AND PREVALENCE
The incidence of hypertension is an epidemic of
world wide proportions. In the United States alone it
has been estimated that as many as 58 million Ameri-
cans have elevated blood pressure and, as a result, are
at increased risk of morbidity and premature mortality(1).
Prevalence increases with age(2) and is more promi-
nent in the black race who also suffer more morbidity
and mortality secondary to hypertesion(3). Regional dif-
ferences in blood pressure have also been observed.
Blacks in the southeastern United States experience
an increased prevalence rate and severity of hyper-
tension as well as increased rate of stroke death com-
pared to blacks in other parts of the country(1). This
association of increased prevalence with race and re-
gional differences has also been found in Brazil(4) and
parts of Africa(5). Therefore this increased prevalence
rate may have implications in other parts of the world(6).
Reducing elevated blood pressure protects against
major cardiovascular complications such as stroke,
congestive heart failure, renal damage, dissecting an-
eurysm, progression of hypertension to a more severe
state and coronary artery disease. Present evidence
indicates that risk increases continuously with increas-
ing levels of systolic and diastolic blood pressure(7).
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While there is consensus to treat hypertension,
the precise levels at which treatment should begin, as
well as specific therapeutic strategies to be prescribed,
are less well agreed upon. The recommendations for
treatment of high blood pressure by expert panels
worldwide illustrates these differences. The 1987 Re-
port of the British Hypertension Society Working
Party(8) and the 1988 Canadian Hypertension Society
Consensus Conference(9) recommend treatment for di-
astolic pressures of ≥ 100 mm Hg for three to four
months; the World Heath Organization and Interna-
tional Society of Hypertension (1985) recommend
treatment for diastolic pressures of ≥ 95 mm Hg; and
the 1988 Fourth US Joint National Committee on De-
tection, Evaluation and Treatment of Hypertension(1),
recommends initiating treatment for blood pressures ≥
94 mm Hg and for blood pressures between 90 and 94
mm Hg when there are associated risk factors. Kaplan
analyzed the differences, and concluded that, “As a
compromise – and likely as the consensus – a diastolic
pressure of 95 mm Hg seems to be the level wherein
therapy has been shown to provide protection. That
level may then be used in the operational definition of
hypertension”(10).
For the purpose of consistency throughout the
remainder of this paper, hypertension will be called mild,
moderate or severe based on the criteria identified by
the 1988 Joint National Committee(1) Table I.
Systolic hypertension may be as important as
diastolic blood pressure as an index of prognosis(7).
Treatment goals should include normalization of sys-
tolic blood pressure (< 140 mm Hg) as well as diastolic
blood pressure. Systolic hypertension should be evalu-
ated and treated with nonpharmacologic and pharma-
cologic interventions as necessary.
Although general guidelines are useful to estab-
lish criteria for treatment, each patient should be con-
sidered individually. The late Sir George Pickering had
long challenged the assumption that a particular blood
pressure level should be considered a cutoff for treat-
ment. He postulated that the risk associated with high
blood pressure is a relative risk and should be viewed
on a continuum: the higher the pressure, the greater the
risk(11). Rose subsequently identified the operational defi-
nition of hypertension as: “the level at which the ben-
efits... of action exceed those of inaction”(12).
2. CURRENT TRENDS
The approach to the management of hyperten-
sion has changed significantly in the last two decades.
Previously, the major emphasis was placed on the detec-
tion of curable forms of hypertension (coarctation of
the aorta, pheochromocytoma, primary aldosteronism,
Cushings syndrome, and renovascular hypertension)
and treatment of premalignant and malignant hyper-
tension. Subsequently it has been demonstrated that the
treatment of primary or essential hypertension results in
a significant reduction in stroke and coronary artery
disease(7), and the major focus has shifted to the de-
tection, evaluation and treatment of all types of hyper-
tension. Since 1972, there has been an increased pub-
lic awareness of high blood pressure and an increasing
number of individuals being treated for high blood pres-
sure. These factors have likely contributed to the decline
in the national age-adjusted stroke mortality (50%) and
the decline in coronary artery disease mortality (35%)
in the United States over the last two decades(1).
Expert panels in the last three years have con-
vened around the world to evaluate the most efficacious
way in which to treat hypertension. The US Joint Na-
tional Committee notes that if the decline in stroke and
coronary artery disease noted in the 1988 report is to
continue, that a number of events must occur including:
• The hypertension control process must be ex-
tended to the entire population, and
• Aggressive treatment must also take into con-
sideration the life-styles and concomitant conditions of
individual patients.
Table I - Fourth Joint Committee Classification of
Blood Pressure (BP)a
Range (mm Hg) Categoryb
Diastolic  < 85 Normal BP
85-89 High normal BP
90-104 Mild hypertension
105-114 Moderate hypertension
≥ 115 Severe hypertension
Systolic (when DBP < 90)
< 140 Normal BP
140-159 Borderline isolated systolic
hypertension
≥ 160 Isolated systolic hypertension
a Classification based on the average of two or more read-
ings on two or more occasions.
b A classification of borderline isolated systolic hypertension
(systolic BP, 140 to 159 mm Hg) or isolated systolic hy-
pertension (systolic BP ≥ 160 mm Hg) takes precedence
over a classification of high normal BP (diastolic BP, 85 to
89 mm Hg) when both occur in the same person. A classi-
fication of high normal BP (diastolic BP, 85 to 89 mm Hg)
takes precedence over a classification of normal BP (systolic BP
< 140 mm Hg) when both occur in the same person(1).
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The increased numbers of therapeutic options,
nonpharmacologic as well as pharmacologic, provides
the opportunity to improve hypertension control while
minimizing adverse effects that may influence the ef-
ficacy of therapy and incur complications.
Endorsing the philosophy that the treatment op-
tions for each person with hypertension must be con-
sidered individually, Dr. Alan Brett wrote; “It is widely
acknowledged that, with successively higher blood pres-
sure levels, the risk of complications increases gradu-
ally rather than abruptly. Therefore, the reasons to in-
tervene should be viewed as gradually more compelling
as blood pressure rises, rather than suddenly compelling
at a specific level such as 90 mm Hg. Each decision
must be individualized, depending on the patient’s
aversion to risk, perception of the intrusiveness of
medical care in his life, tolerance for discomfort or
untoward drug effects, etc”(13). Careful attention
need therefore be taken with each patient to
choose the most appropriate, least intrusive and spe-
cific nonpharmacologic and/or pharmacologic
intervention(s).
The goal of treating patients with hypertension
is to prevent morbidity and premature mortality asso-
ciated with elevated blood pressure. The objective
is to achieve and’maintain blood pressure measure-
ments below 140/90 mm Hg(1). In choosing the appro-
priate treatment one must consider the severity of blood
pressure elevation and the presence of other com-
plications.
The following flow chart illustrates this concept
(Figure 1).
Figure 1 - Recommendations for the definition and management of mild hypertension organized by participants at the Third
Mild Hypertension Conference of the World Health Organization and the International Society of Hypertension. (From World
Health Organization/International Society of Hypertension. J Hypertens 7: 689, 1989). BP: blood pressure.
Diastolic BP measured three times
on  two different  occasions: if mean
pressure is 90-104 mm Hg
Repeat measurements on at least
two  further days  over a period of
4 weeks
Diastolic  BP  below  90  mm  Hg:
further measurements at 3-month
intervals for a year
Diastolic BP below 90-94 mm Hg:
institute  non-drug  treatment and 
monitor blood pressure
Diastolic  BP  below  100  mm  Hg: or
above: reinforce  non-drug measures 
and institute drug treatment
Diastolic BP below 95-99 mm Hg:
reinforce non-drug measures and
consider  drug  treatment  if other
risk factors present
Diastolic BP below 90-94 mm Hg:
reinforce non-drug measures and
monitor blood pressure
Diastolic  BP  below 90-94 mm Hg:
no other risk factors: continue non-
drug  treatment and  monitor blood
pressure
Diastolic BP below 90-94 mm Hg:
with  other  risk  factors:  consider
drug treatment
Diastolic BP below 95-99 mm Hg:
with  or  without  other risk factors 
consider drug treatment
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Within the context of this treatment paradigm,
the present paper will focus on the nonpharmacologic
interventions. After a general introduction, each inter-
vention will be discussed separately and in detail, con-
sidering ways to apply it to a general population and
taking into consideration the lifestyles and concomi-
tant conditions of individual patients.
3. NONPHARMACOLOGIC TREATMENT OF HY-
PERTENSION
There is endorsement from the World Health
Organization(6), the Joint National Committee for the
Detection, Evaluation and Treatment of Hypertension(1),
the Canadian Consensus Report Society for Hyper-
tension(9) and the British Hypertension Society Work-
ing Party(8) concerning the efficacy of nonphar-
macologic approaches. Recent evidence cited by these
panels suggests that nonpharmacologic therapies may
lower elevated blood pressure and improve the effi-
cacy of pharmacologic agents. In this context, nonp-
harmacologic interventions can be used both as a de-
finitive intervention in mild to moderate hypertension
(diastolic ≤ 114), and as an adjunct to pharmacologic
therapy for those individuals with severe hypertension
(diastolic ≥ 115 mm Hg) or the presence of other sig-
nificant risk factors.
In view of the fact that 80% of those individuals
diagnosed with hypertension have mild to moderate
elevations of blood pressure (90 - 104 mm Hg),
nonpharmacologic therapies should be used as initial
therapy for most patients, at least for the first three to
six months after recognition of their hypertension. For
those 40% of patients with diastolic levels between 90
and 94 mm Hg, nonpharmacologic therapy may be
sufficient to reduce blood pressure to the recommended
normotensive level(14). Systolic blood pressure reduc-
tions between ten and 15 mm Hg and diastolic blood
pressure reductions between six and 10 mm Hg are
typically achieved in nonpharmacologic intervention
programmes(15). This is clinically significant since it has
been estimated that each four mm Hg reduction in blood
pressure is accompanied by a 10,8% decrease in car-
diovascular risk(16). The modest decrease in blood pres-
sure associated with nonpharmacologic therapies has
an additional benefit since it has been demonstrated
that reductions of greater than 10-20 mm Hg are asso-
ciated with increased morbidity and mortality. As many
as 20 to 25% of patients with mild hypertension can
become normotensive with nonpharmacologic interven-
tions. Medicated hypertensive patients who add
nonpharmacologic treatments to their regimens may
be able to maximize blood pressure control on a mini-
mum of antihypertensive medications.
Advantages of nonpharmacologic approaches
are reduction in adverse pharmacologic side effects as
well as medication costs. In addition, and significantly,
nonpharmacologic interventions generally address the
entire risk profile.
4. EFFECTING BEHAVIOURAL CHANGE
4.1. Clinician responsibility
While most clinicians treating hypertension now
consider nonpharmacologic treatments to be effective,
particularly for patients whose diastolic pressures are
between 90 and 94 mm Hg, the practical issues re-
garding patient motivation, monitoring, and engineering
behaviour change can appear formidable. A legitimate
concern of many clinicians is whether such interven-
tions can be successfully and practically accomplished.
They are not comfortable instituting and monitoring the
behavioural changes required. Whereas most clinicians
support, at least in theory, the use of nonpharmacologic
treatment of mild hypertension, very little time is usu-
ally spent counseling patients with respect to the
behavioural interventions required.
The reasons for this discomfort are threefold.
First, an overwhelming majority of clinicians (particu-
larly physicians) feel that their training did not ad-
equately prepare them for counseling patients on how
to bring about the important behavioural changes re-
quired. Consequently, the use of nonpharmacologic
treatment approaches for hypertension may be more
inhibited by physicians discomfort with teaching be-
havioural change than by the ability of the interven-
tions to bring about the desired goal. Second, many
physicians report little confidence in the effectiveness
of their recommendations for nondrug approaches to
hypertension control. Third, most physicians report that
there is little time in an office visit to bring about be-
havioural change. Nurses feel better prepared to ad-
dress behavioural change and endorse its value and util-
ity, but also find little time to accomplish this objective.
To address these issues clinicians need to con-
sider the scope of what can be accomplished in the
office as well as to consider referring their hyperten-
sive patients for nonpharmacologic treatment to cen-
ters or practitioners who routinely engage in this type
of endeavor.
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4.2. The role of belief
The personal bias of the clinician toward the cost/
benefit of changing a specific behaviour also needs to
be considered. If a clinician believes that exercise is
unpleasant, that losing weight means giving up every-
thing that tastes good, and that it is difficult to change a
lifestyle behaviour, it is likely that this practitioner will
not be as effective in helping a patient engineer
behavioural change as will a clinician who holds a more
positive view. An explanation stems from an under-
standing of the mechanisms responsible for the pla-
cebo effect.
Eliciting the placebo effect is dependent on three
factors: the belief of the practitioner, the belief of the
patient, and the relationship between the patient and
practitioner(17). In studies conducted by investigators
who enthusiastically endorsed the validity of the inter-
vention being studied, the results were more likely to
be positive than studies done by skeptics(18). It is likely
that the enthusiastic clinicians conveyed their belief in
the value of the intervention to the patient, and that this
directly influenced the outcome. Thus, the belief of both
clinician and patient is inherently important.
A recent study illustrates this point. Horowitz et
al reanalyzed the results of the Beta Blocker Heart
Attack Trial, controlling for adherence(19). The rela-
tionship of medication adherence to mortality in the
first year after a myocardial infarction was investigated
among 2,175 participants. Those who did not adhere
well to their medication regimen (i.e., who took less
than 75% of their medications) were 2.6 times more
likely to die than were those who did adhere to their
medication regimen (i.e., who took more than 75% of
their medication). The surprising finding in this study
was that those participants assigned to placebo had
approximately the same death rate when they did not
adhere to their placebo medication regimen (2.5% in-
cidence of death) as did those assigned to a Beta-block-
ade group (3.1% incidence of death). This would sug-
gest that not adhering to a prescribed medication
regimen increased mortality in the first year following
myocardial infarction and that the increase in mortality
occurred irrespective of whether the person took pla-
cebo or active ingredient. From this it might be con-
strued that the act of taking medication (belief) might
be the active ingredient rather than the pharmacoki-
netics of the drug itself. In the current environment
where both patient and clinician highly value medica-
tion in the treatment and cure of illness, the depth of
this belief becomes apparent. This study illustrates the
utility of harnessing the power of the patients belief in
effecting optimal outcomes.
Therefore it becomes more important for the
clinician to engender belief that the intervention is valu-
able, that the benefits of the treatment exceed the cost,
and that the patient can be successful in effecting the
change.
Data describing reactions to the diagnosis of hy-
pertension also emphasize the role of beliefs. One risk
attendant in labeling an individual as “hypertensive” is
to evoke the assumption of the sick role. There has
been so much, albeit necessary, education about the
dangers and risks associated with hypertension, that
much of the public holds a strong opinion about this
diagnosis. In one frequently cited study, the diagnosis
of hypertension, without any change in symptoms, was
accompanied by an immediate increase in absentee-
ism from work(20). This is not a trivial effect. In a Ca-
nadian study the average yearly income of 230 hyper-
tensive steel workers was an average of $1093 less
than for a matched group of normotensives, despite
similar incomes in the year before diagnosis(21).
MacDonald et al. concluded in a review article that
people who are labeled, but who receive appropriate
counseling, support and care and who are compliant
with therapy usually do not have increased absentee-
ism or psychological distress(22). Clearly this phenom-
enon needs to be considered and clinicians need to
address this directly with patients. In this context, fam-
ily, societal and culture beliefs which also profoundly
affect the patient’s perception of health, illness and
treatment need to be considered.
4.3. Antecedent factors which influence the
treatment of hypertension
In assessing an individual’s motivation and readi-
ness to adopt healthy behaviours to prevent and/or ad-
just to illness and to change adverse lifestyles, the role
of antecedent factors must be considered.
It is perhaps a paradox that in the health care
system the greatest percentage of resources are allo-
cated to medical care, while precious few resources
are dedicated to understanding and treating those
behaviours which underlie illness. In 1979 Joseph
Califanos MD, then the US Surgeon General, issued
Healthy People: The Surgeon General’s Report on
Health Promotion and Disease Prevention(23). This
report noted that as many as half the premature deaths
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The physiological risk factors which predict the
development of cardiovascular disease include hyper-
tension, hypercholesteremia, smoking, sedentary
lifestyle and stress, as well as others. But each physi-
ological risk factor – in this example hypertension – is
directly influenced by behavioural antecedent factors
including a diet high in sodium, fat and calories with too
little exercise, too much stress, and social pressure to
smoke and consume alcohol.
Each individual has a set of values, preferences
and meanings which greatly influence their attitude to-
ward life, health and health seeking behaviours. Sev-
eral conceptual models have evolved to explain the
role of values and beliefs in predicting treatment out-
comes and adherence. One of the most popular, the
Health Belief Model proposes
that in order to be successful
in effecting behavioural
change, the individual must
perceive the benefits of
change as outweighing the
cost of change(25). Other
theories, including Locus
of Control(26) – either inter-
nal or external – and Self-Ef-
ficacy(27) – how successful
the individual believes that
they can be in bringing about
change, acknowledge that the
individual’s perception of their
role in their care greatly in-
fluences the outcome.
These personal belief
systems should be viewed in
conjunction with the family,
social and cultural norms
which nurture them. In the
society of two-income families, for example, fast food
and prepared food are becoming the norm. These foods
are high in calories, fat and sodium, and lacking in po-
tassium and other important nutrients. This eating pat-
tern is reinforced by commercial practices which mar-
ket the attractiveness of these products to busy families,
and laws which do not promote labeling which might
educate the consumer. Underlying and supporting the
pyramid are cultural values and beliefs which support
the notion of freedom of choice with minimal regulation
and restriction.
Clearly, the primary concern of the health care
system and the clinician has been at the top of this
in the United States may be due to unhealthy behaviours
or lifestyles. It suggested that of the ten leading causes
of premature death in the United States, at least seven
could be substantially reduced if Americans altered their
lifestyles. These lifestyles included poor diet, smoking,
lack of exercise, alcohol excess, and unhealthy re-
sponses to tension and stress. In 1991, while the tech-
nology available to treat the complications of hyper-
tension have advanced tenfold since 1979, there are
still few monetary resources dedicated to understand-
ing and promoting health seeking behaviours.
Figure 2 is a conceptual framework developed
by Tarlov which allows consideration of relevant fac-
tors as they apply to the genesis of illness.
Figure 2 - Underlying factors in the genesis of illness (ill health). From: The rising
supply of physicians and the pursuit of better halth. Tarlov AR. Journal of Medical
Education. 1988; 63: 104.
In the above illustration, ill health is viewed as
being at the apex of a pyramid of antecedent underly-
ing factors, in which the medical/cultural value plays a
role(24). The way in which this model relates to cardio-
vascular disease in general and hypertension in par-
ticular will be described. Priorities in research funding
to study the prevention and treatment of hypertension
have favoured genetic causes or new interventional
techniques. There is no doubt that genetic factors play
an important role. But these genetic factors are influ-
enced by a variety of other factors which can trigger
and/or overwhelm biology and predilection to develop
hypertension.
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pyramid, the diagnosis and treatment of ill health. In
order to treat hypertension effectively, considering the
multiplicity of antecedent factors, it is important to view
each individual patient as a biopsychosocial being, and
to intervence with a specific understanding of these
myriad factors. In addition, clinicians should concern
themselves with the broad public health policies which
influence progress towards achieving the desired blood
pressure objectives.
4.4. Stages of change
Clinicians need not become behavioural change
experts to endorse the utility of nonpharmacologic
therapy, or to treat their patients using these approaches.
Once the specific problems have been identified, the
first step for the clinician is to endorse the value of
nonpharmacologic therapy. It is important to engender
confidence on the part of the patient that they can be
successful in changing adverse behaviours, and that
the practitioner will be there to help them.
A second step involves the endorsement of the
patient’s participation in a programme that is specifi-
cally designed to bring about the desired changes.
The third step is a willingness to reinforce the
changes once the programme is completed when the
patient returns for follow-up care.
These are realistic goals for a clinician to ac-
complish within the context of a brief office visit. It is
not always practical or cost effective to establish pro-
grammes within their office to bring about the behav-
iour change required for successful nonpharmacologic
interventions. It is, however, crucial to appropriately
motivate and empower patients.
Patients who are appropriate candidates for non-
pharmacologic intervention may be at a variety of stages
regarding their readiness to change. It is imperative
for the clinician to assess the patient’s readiness to
change and to intervene in the most effective manner.
Drs. Prochaska and DiClemente, have described four
stages of change. These are: precontemplation
(no information, or not interested, not motivated), con-
templation (interested, motivated), action (ready to
change, motivated), and maintenance (including relapse
prevention)(28).
The relationship between implementation of
nonpharmacologic treatments for hypertension and the
decision making stage of a hypertension patient is cru-
cial. The first goal of the clinician would be to assess a
patient’s stage regarding his condition.
For some hypertensive patients, the initial issue
involves presenting the importance of lowering blood
pressure and reducing other cardiovascular risk fac-
tors. Some patients simply do not know that high blood
pressure is dangerous and should be lowered. Others
may appreciate the fact that high blood pressure should
be lowered, but will assume that only drugs can be
effective. Both types of patients are at the precon-
templation stage. The clinician’s primary responsibility
is to communicate the importance of reduced blood
pressure and to indicate the effectiveness of nonphar-
macologic interventions. For patients in the precon-
templation stage, the clinician should not only commu-
nicate the effectiveness of such interventions but also
assess the patient’s willingness to help achieve the
goals.
Once patients have moved past the precontem-
plation stage into the contemplation stage, more spe-
cific information is required. For example, at this stage,
a discussion about the ways in which dietary salt can
be reduced should occur. The patient’s anticipated dif-
ficulties associated with making behavioural changes
should also be considered. Precise information con-
cerning the ways in which the programme can be imple-
mented should be discussed.
During the contemplation stage, the clinician
should explain the potential benefits of exercise, tech-
niques to elicit the relaxation response, and stress man-
agement to the patient. The transition from the con-
templation stage to the action stage requires a
presentation which does not threaten the patient. Of
course, behavioural change can be difficult and patients
should not be misled. However, systematic programmes
on life-style change to reduce cardiovascular risk need
not be overwhelming. In the contemplation stage, the
clinician must carefully set the stage for action. He or
she must let the patient know that the action plan will
occasionally cause some frustration and relapsing
and although this is normal and expected, success is
possible.
Many patients tend to approach the contempla-
tion stage with an ambivalent attitude. They may per-
ceive attempts to intervene nonpharmacologically as
attempts to “get me to stop doing everything I enjoy
and get me to do everything I hate”. Obviously, this
would need to be addressed in order to move a patient
to the action stage. It is often useful at this point to
have the patient complete some type of values clarifi-
cation exercise. In this way the patient can view the
cost/benefit ratio of changing in relation to the larger
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issue of what they value. Another useful strategy is to
have the patient review past experiences with success-
ful behaviour change, and then to engender the expec-
tancy that they can be successful in this endeavor. Pre-
senting the intervention in light of what patients can
do instead of focusing on with they cannot do, is im-
portant in engendering a positive attitude and engineer-
ing a successful outcome.
Once patients have entered the action phase,
specific, measurable, incremental goals should be mu-
tually agreed upon, stated and monitored. During the
contemplation stage, patients become convinced, for
example, that sodium restriction or weight loss is both
necessary and possible. During the action stage, agreed
upon reductions below 2,000 mg per day and weight
loss of one and a half pounds per week must be moni-
tored. Clinicians should focus on imparting critical in-
formation, teaching appropriate self-care skills and en-
gendering a positive attitude in order to accomplish
these behavioural changes(29). The patient should feel
a sense of partnership in achieving goals, and a sense
of individual responsibility consistent with a selfcare
approach should be developed.
The clinician’s knowledge concerning nonp-
harmacologic interventions and their utility in hy-
pertension treatment is usually all that needs to be com-
municated to the patient to move him or her from
precontemplation to the contemplation stage. More of
a dialogue concerning feasibility and more apprecia-
tion of the patient’s particular circumstances and
strengths is usually required to move the patient to the
action stage. Once there, however, a fundamental de-
cision needs to be made. The decision concerns the
implementation of the intervention plan. In many, if
not most cases, the clinician will not be practically
prepared to initiate the type of systematic and com-
prehensive plan which will most likely lead to suc-
cess. In these cases we recommend referral to spe-
cialized programmes which assess the patient
utilizing a biopsychosocial model, whose interven-
tions address konowledge development, skills ac-
quisition, and attitude, and which include the patient
as a partner in care. A group format may be most
advantageous in this regard, providing structure
and social support as well as being more cost ef-
fective.
For those patients who are motivated and inter-
ested in pursuing behavioural change on their own, the
referring clinician should follow a similar format but
more of the responsibility for knowledge development
and skills acquisition falls to the patient. Goals should
be mutually agreed upon The patient should seek out
information and resources for self-help which will pro-
vide the structure for their intervention. The clinician
should assess and monitor the patient’s progress.
Prior to completing the intervention or action
phase, it is important to provide patients with a frame-
work for maintenance and relapse prevention. They
need to learn specific self-monitoring skills such as di-
ary keeping, home blood pressure measurement,
weekly weights, and fat-gram counting, as well as many
others. Patients need to learn to anticipate high risk
situations when lapses and relapses may occur, and
they need to know when to seek help to prevent a lapse
becoming a more entrenched situation. The patient
should understand that movement through the stages
of successful behaviour change is bidirectional and cir-
cular, not linear. This is important. When a person does
encounter a lapse, they should not feel that it is the end
of the line, but rather that they can move back into
action, or around to precontemplation and begin again.
The referring clinician is critical in assisting the patient
to maintain the health gains which they have achieved.
Periodic review of the patients progress and self-moni-
toring data are important to validate the self-care
role of the patient and reinforce the hard won gains
which they have achieved. Adherence to nonpharma-
cologic intervention strategies will not be uniform and
estimates of compliance vary widely. While adherence
to nonpharmacologic therapy is certainly an issue, ad-
herence to antihypertensive pharmacologic regimens
also represents a significant challenge to the clinician.
This however is hardly a reason to abandon either phar-
macologic or nonpharmacologic treatment.
In spite of a clinician’s best efforts, there are
some patients who do not desire to approach their
medical problems from a nonpharmacologic, behav-
ioural perspective. Some cannot easily accept the ra-
tionale for reducing medical symptoms using behav-
ioural strategies; others may see the “cost” in personal
terms as outweighing the benefits. For a variety of rea-
sons, the patient may be unwilling or unmotivated to
make the required behavioural changes at this time. It
is, however, vital in these situations to follow-up at the
next visit, because the patient may be ready at that
time. Additionally, a referral to a Behavioural Medi-
cine clinician might be helpful.
Figure 3 is a flow chart which delineates the
decision making process for effective behavioural
change.
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Figure 3 - Decision making matrix for behaviour change.
5. NONPHARMACOLOGIC INTERVENTION
STRATEGIES
There are some well-established, nonpharma-
cologic, antihypertensive therapeutic interventions:
weight reduction, sodium restriction, reduced alcohol
consumption, exercise, elicitation of the relaxation re-
sponse, stress management, and smoking cessation.
The procedures by which these nonpharmacologic in-
terventions can be coordinated into an effective treat-
ment programme will be described later.
In prescribing these nonpharmacologic interac-
tions for individual patients, one problem which remains
is the heterogeneity of response,. A fundamental ques-
tion concerning the utility of nonpharmacologic treat-
ment strategies for hypertension concerns therapeutic
efficacy for the individual as well as the aggregate. In
addition, the diagnostic process and prescription of
nonpharmacologic therapies often lacks precise sensi-
tivity and specificity. An obvious example is that of
weight reduction. While an obese patient can signifi-
cantly reduce blood pressure with weight loss, a thin
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hypertensive patient would be unlikely to benefit from
this strategy. Due to differences in underlying patho-
physiologic mechanisms, some hypertensive patients
may be more or less likely to profit from exercise train-
ing, sodium restriction or elicitation of the relaxation
response.
While the presence or absence of some relevant
characteristics are easily determined such as obesity
and smoking, other factors are less easily observed,
for example, sodium insensitivity and exercise condi-
tioning. Therefore, careful attention needs to be paid
to assessing the risk profile as carefully as possible
and intervening in the most specific manner.
In the following pages, each of the nonphar-
macologic components will be described separately
before presentation of a comprehensive treatment
approach.
5.1. Weight reduction
5.1.1. Scientific rationale for weight reduction
Weight reduction for obese hypertensive patients
should be the first treatment strategy for mild hyper-
tensive patients and a complementary treatment strat-
egy in all obese patients requiring drugs. There is
consensus in the literature that obesity is commonly as-
sociated with hypertension(30). A strong correlation
between body weight and blood pressure, and between
increased body weight and increased blood pressure
has been demonstrated(31).
Conversely, a decrease in body weight corre-
lates with a decrease in blood pressure(32). The mean
effect of a one Kg fall in body weight is a 1.6/1.3 mm hg
fall in systolic/diastolic blood pressure(33). Further, sig-
nificant reductions in blood pressure can be achieved
with only modest decreases in weight(34). Weight re-
duction intervention is recommended for patients who
are more than ten to 20% above ideal body weight
(IBW). Body mass index (BMI), hip/waist measure-
ment and percent body fat should also be taken into
consideration.
The issue of whether weight reduction will low-
er blood pressure without sodium restriction is still de-
bated. The US Joint National Commission stated that
weight reduction may occur with calorie restriction
alone, even without reduction in sodium intake and
before ideal body weight is achieved. Kaplan(33), how-
ever, reviewed a variety of studies including one by
Fagenberg et al who found little antihypertensive ef-
fect associated with weight loss without concomitant
sodium restriction(35). The majority of studies reviewed
do not isolate the two interventions(36).
There appear to be three mechanisms by which
weight loss effects lowered blood pressure. The initial
response to a low calorie diet is natriuresis, with an
accompanying decrease in weight(37). Thereafter, a
decrease in sympathetic nervous system activity(38), and
a decrease in plasma insulin occurs(39).
5.1.2. Behavioural strategies for weight reduction
Clinicians should vigorously promote weight con-
trol, particularly in those with a family history of obe-
sity. This recommendation is made with full understand-
ing of the difficulties in engineering this change, and
the high rate of relapse. Weight loss programmes for
hypertension must be considered in conjunction with
the cultural and socioeconomic situations confronting
patients. In some impoverished societies, obesity is
not a widespread problem. In other societies, these
may be little social pressure to lose weight, while
the social pressure to be thin in other societies may
be great.
It is unlikely that obese hypertensive patients will
substantially alter their behaviour concerning body
weight just because they became aware of the rela-
tionship between body weight and blood pressure. Cli-
nicians must not only educate, but also motivate pa-
tients to begin the difficult behaviour change process.
Taking the time and effort to appreciate the patients
perspective on weight loss is important. Developing a
practical and effective programme requires sensitivity
to the life circumstances of the patient. Very low ca-
loric formulas can be effective (short term) and safe(40).
However, these formulas are expensive and require
careful medical supervision. Less stringent diets com-
bined with exercise and behavioural techniques also
work(41). However, these programmes must be rigor-
ously and systematically implemented. Weight reduc-
tion should be approached as a multifaceted problem
(Figure 4). In addition to education regarding the nutri-
tional, caloric and fat content of food, the patient should
be instructed in label reading, menu selection and food
preparation. They should be encouraged to exercise,
elicit the relaxation response and investigate the
behavioural aspects of their eating patterns. Assess
not only what people eat, but where, when and how
they eat. It has been estimated that 50% of meals eaten
by the typical American are eaten away from home or
in front of a television. In addition to addressing indi-
vidual differences, food plans should be flexible, enjoy-
able and focus on those things the patient can eat rather
than those things that they can not.
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The specifics of the intervention for obese hy-
pertensive patients do not differ greatly from those
usually applied to other obese patients. Patients need
to be apprised of healthy eating choices available to
develop an increased awareness of dietary habits. This
requires careful attention to monitoring food intake
Figure 4 - Decision making matrix for weight reduction. IBW: Ideal body weight; BMI: body mass index.
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and behavioural habits on a consistent basis. Self-
monitoring both food intake and progress towards
goals – through a food diary and weekly weights – are
critical to a successful programme. The food recall
diaries should be for three or more days, some clini-
cians express reservations about the accuracy of these
recalls. However, many intervention programmes re-
port that the technique can be successful if it is intro-
duced as a way for the patient to contribute to their
care, and if they understand that successful weight loss
depends on accurate record keeping.
The positive aspects of diet planning should be
stressed, and the patient should be encouraged to de-
sign their own strategies for change. It is not enough
to tell the patient that he should not eat high calorie
snacks. The patient needs to plan what he will snack
on when he sits down to watch television, or to avoid
the television by taking a walk. Anticipating hurdles
and high risk or tempting situations is important, and
contingency plans should be developed. Initial adher-
ence to the food plan is highly predictive of long-term
compliance, therefore it is important to programme an
early success(42). The patient should learn that foods
lower in calories also tend to be lower in saturated fat
and sodium thereby maximizing cardiovascular ben-
efits. Impress upon the patient that dietary change re-
quires dedication and commitment. Again, the dietary
changes recommended must be developed with a sen-
sitivity to the environment in which the patient lives.
An example of the sensitivity required is illus-
trated by the important difference a clinician would
need to maintain in developing a programme for a group
of affluent hypertensive women in a suburban United
States community as compared to a group of poor in-
ner-city women in the United States. Advice concern-
ing available food choices, specific exercise activities
and medical supervision should account for the dra-
matic differences in personal resources, food choices,
community resources and access to medical care be-
tween the two groups. Monitoring progress on a regu-
lar basis is necessary to achieve optimal adherence.
Dietitians are important collaborators in achieving these
ends. Realistic expectations concerning weight loss are
also necessary. The short-term goal is weight loss of
between one to 1.5 pounds each week. The long-term
goal is to achieve and maintain body weight within ten
percent of ideal body weight.
Advice to “lose weight” or “cut back”, no mat-
ter how well-intentioned, will not likely yield positive
results. Most weight loss programmes succeed in the
short term, but fail in the long run. Those programmes
based on behaviour modification principles and which
include exercise and psychological factors such as elici-
tation of the relaxation response and stress manage-
ment work better than approaches which do not in-
clude these components. In our experience, patients
do best when referred to programmes which offer a
comprehensive approach to weight loss as part of our
overall risk profile. The referral process for this inter-
vention and for all other nonpharmacologic therapy is
a crucial aspect of the treatment. Clinicians should en-
thusiastically endorse weight loss as a way to reduce
blood pressure and lower cardiovascular risk. They
should also convey their firm belief that the patient can
succeed. Long-term maintenance is enhanced with
appropriate follow-up support.
5.2. Sodium restriction
5.2.1. Scientific rationale for restricting sodium
The US Joint National Commission stated that
“a high sodium intake plays a critical role in maintain-
ing the elevated blood pressure of some hypertensive
patients and in limiting the effectiveness of certain an-
tihypertensive drugs”(1).
The Canadian Consensus Report(9), the World
Health Organization(7), and the Australian National
Health and Medical Research Council(43), concurred.
Kaplan points out that some controversy about the
utility of sodium restriction remains, however(44). This
controversy is most likely due to the fact that precise
measures to determine who will benefit from this in-
tervention are not available. The effects of sodium re-
striction on individual patients cannot be predicted with
certainty. Although this diagnostic ambiguity exists, it
is also true that sodium restriction has been shown
generally to be beneficial in lowering blood pressure,
and moderate restriction has not been associated with
any serious adverse consequences(1).
There is a consensus that modest restriction of
dietary sodium – 70 to 100 mmol/day – will lower blood
pressure four to eight mmhg below levels seen with a
baseline diet which is high in sodium(32). Not only is
there a correlation between decreased sodium intake
and decreased blood pressure, but most patients can
successfully adhere to this diet. As noted previously
however, not all patients will show a decrease in blood
pressure with a modest reduction in sodium. Initial blood
pressure may be the most important factor related
to the effect of sodium restriction; the higher the initial
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level, the greater the reduction(45). In general, eld-
erly and black hypertensive patients seem to benefit
from sodium restriction more than young and white
patients. Genetic factors have been cited as predis-
posing individuals to respond to sodium restriction,
but this theory is not universally endorsed(36).
Although the precise mechanism by which so-
dium restriction lowers blood pressure is not agreed upon,
there are several hypotheses which have evolved to
explain the relationship between sodium intake and
blood pressure regulation. Of these, the autoregulation
theory, the natriuretic hormone hypothesis and altered cel-
lular membrane function have been widely accepted(36).
Table II summarizes the recommended changes
in the consumption of dietary fats, cholesterol, sodium
and fiber, and demonstrates the potential impact of
these changes(42).
2,000 mg per day is ten times above the necessary
metabolic requirements. The problem however is that
the average American may ingest between 8,000 and
9,000 mg of sodium per day, and their taste prefer-
ences are nurtured to enjoy salt. In view of the ben-
efits of restricting sodium, why are these diets not more
widely followed? In 1972 Dahl(46) put forth three rea-
sons which are still appropriate. First, we are accus-
tomed to the taste of salty food since infancy. Second,
most clinicians prescribe low sodium diets unenthusi-
astically and haphazardly. And third, these diets may
initially seem complex, and discourage patients. In 1991,
we might add a fourth reason, social and cultural norms
which promote fast/prepared/processed food. Currently
there is a compelling need to consider additional, pow-
erful deterrents to reducing sodium. Nearly 60 to 80%
of our daily sodium intake in the United States(47),
Canada(48), and England(49),
comes from processed food, and
this food may be inadequately la-
beled. In addition, in the United
States, it is estimated that twenty
percent of our meals are “fast
food”, which are typically high in
sodium and fat(49). The sensitivity
to the individual circumstances of
a hypertensive patient, which we
discussed regarding weight loss,
is also required when addressing
sodium restriction. There are oc-
casionally practical barriers to so-
dium restriction. For example, in
some cultures and among some
ethnic groups, salty food is the
norm. Asking patients to shop dif-
ferently, cook differently and eat
in different restaurants, impacts
on family members as well as pa-
tients themselves. Careful plan-
ning and cooperation between
clinician and patient can usually
overcome these difficulties.
In spite of these difficulties,
the successful completion of many of the trials cited in
this paper demonstrates the ability of people to adhere
to a moderate sodium restricted diet. While ethnic and
cultural preferences need to be considered, this need
not be a barrier to treatment. Rose has described a
successful community intervention trial in rural Portu-
gal where the predominant local diet was high in
sodium(50).
5.2.2. Behavioural strategies to reduce daily so-
dium intake
Most agree that for sodium restriction to be thera-
peutically efficacious daily consumption needs to be
reduced to or below 2,000 mg. Some patients find this
difficult, although in our experience, it is a realistic
and attainable goal. To place this goal in perspective,
Table II - Diet changes and benefits
Current and recommended dietary intakes
Nutrient Current intake Recommended
Dietary fat 80-100 g (40%) 40-60 g (30%)
Cholesterol 350-400 mg 300 mg
Sodium 150-200 meq 70-100 meq
Fiber 10-15 g 25-30 g
Potential benefit from diet changes
Diet Diet intake BP/Cholesterol change
Sodium 70-100 meq/day DBP ↓ 2-8 mmHg
(20-40% reduction)
Weight 10-15 lb (4-7 kg) DBP ↓ 4-10 mm Hg
weight loss  cholesterol ↓ 30-60 mg/
dL
Fat 30% fat (phase 1) cholesterol ↓ 30-45 mg/dL
20% fat (pahse 2) cholesterol ↓ 45-60 mg/dL
From: Leon AS. Weight Loss In: New Approaches to Cardiovascular Risk
Management(42).
DBP: Diastolic blood pressure.
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Begin by evaluating the patient’s diet recall for
a minimum of three days assessing sodium content and
the presence of prepared/processed foods (Figure 5).
Ask the patient how often they eat out. Positive feed-
back may be provided by cheking the random urine
sodium which may demonstrate adherence to a low
sodium diet. Although only useful as a relative number,
random sodium provides feedback and can be a posi-
tive incentive for patients if they are adhering to their
diet and see the numbers go down(51). Simply modifying
Figure 5 - Decision making matrix for sodium reduction
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food purchases and preparation can achieve a reduc-
tion in sodium and an accompanying decrease in blood
pressure(52). In addition, patients should also be in-
structed in label reading, menu selection, and food
preparation. It is helpful to let patients know that it
takes approximately one month after reducing sodium
for the taste buds to begin to recover and to appreciate
flavors once again.
Sodium restriction pays dividends in a variety of
ways. When patients become more aware of their so-
dium ingestion, they have a tendency to restrict their
total caloric intake as well, thereby facilitating weight
loss. Additionally, there is a tendency to eat less “fast”
and/or “junk” food.
5.3. Alcohol
5.3.1. Scientific rationale for reduction of alco-
hol
Alcohol comsumption has been associated with
elevations in blood pressure in a number of large popu-
lation studies(53-56) and a reduction in alcohol consump-
tion is associated with a reduction in blood pressure(57,58).
The relationship between alcohol consumption and el-
evations in blood pressure is more evident for systolic
than diastolic blood pressure(36). There are differences
in response to alcohol. The strongest association be-
tween alcohol consumption and elevations in blood
pressure have been shown in men, white people, and
those over 55 years of age(59). The mechanism by
which alcohol appears to work is an acute pressor ef-
fect(56). Each daily alcoholic drink increases the sys-
tolic blood pressure by 0.9 mm hg(60).
In addition to elevations in blood pressure, ex-
cess alcohol intake may decrease adherence to therapy(1),
reduce the effectiveness of antihypertensive medica-
tions(61), and occasionally increase the incidence of re-
fractory hypertension(1).
5.3.2 Behavioural strategies for reducing alcohol
intake
Excess alcohol consumption is one of the most
treatable causes of hypertension and modification of
this behaviour should always be attempted (Figure 6).
To lower blood pressure in those who consume alco-
hol, limit their alcohol intake to one ounce (30 ml) of
ethanol daily. One ounce (30 ml) of ethanol is two ounc-
es (60 ml) of 100-proof whisky, eight ounces (240 ml)
of wine or 24 ounces (720 ml) of beer(1). Modest varia-
tions of these specific recommendations appear in other
reports(6,8 9). The clinician should address this issue with
any patient who has hypertension and who consumes
alcohol, because when made aware of the relationship
between alcohol and elevated blood pressure, most pa-
tients who are not alcohol dependent can make appro-
priate adjustments(62).
As was the case for weight loss and salt restric-
tion, engineering reduced alcohol consumption requires
sensitivity to individual patient needs. While most pa-
tients can easily adjust alcohol consumption to help
control hypertension, there are those who cannot. Al-
cohol consumption is for many people an important as-
pect of social and family life. It is also, unfortunately, a
coping mechanism for many. Patients dependent on
alcohol may have difficulty making the necessary ad-
justments. To ascertain this, the following questions may
be asked and have been shown to predict alcohol de-
pendence: 1 - Has your family every objected to you
drinking? 2 - Did you every think you drank too much?
3 - Have others (friends, physicians, clergy) ever said
you drank too much?(63). If the answers are affirma-
tive, the individual should be referred for counseling.
5.4. Exercise
5.4.1. Scientific rationale for exercise
Although regular physical exercise is standard
practice to lower blood pressure, controversy remains
regarding its effectiveness as a singular therapy. In
their most recent position statement, the Joint National
Committee on Detection, Evaluation and Treatment of
Hypertension concluded that “regular aerobic exercise
(walking, bicycling, jogging or swimming) facilitates
weight control and may be helpful in reducing blood
pressure”(1). The World Health Organization(6) and the
Canadian Consensus Panel(9) concluded that the ef-
fectiveness of exercise in lowering blood pressure has
not been convincingly demonstrated, and stated that
they could not issue any recommendation at this time.
Interest in exercise as a therapeutic modality to
lower blood pressure has been longstanding. Several
large cohort studies have suggested that sedentary in-
dividuals were at greater risk for developing hyperten-
sion(64), and that active individuals had lower blood pres-
sures than their sedentary counterparts(65-72). These
studies are likely confounded by the fact that those
who exercise and become fit may be more predisposed
to manage their weight, eat a healthier diet which is
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ever the results have not been clearcut and the studies
are flawed by methodologic issues(74). These studies
have demonstrated the positive effects of exercise on
weight reduction, insulin resistance(75), blood lipids(76),
and psychological stress(77,78).
Figure 6 - Decision making matrix for alcohol reduction
1 oz (ounce): 29.6 ml
low in sodium, and fat, consume less alcohol, and be
less stressed. Many studies of both normotensive and
hypertensive people have demonstrated a moderate,
clinically significant reduction in systolic and diastolic
blood pressure with regular aerobic exercise(73). How-
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The precise mechanism by which exercise may
lower blood pressure is unclear. During exercise, sys-
tolic blood pressure rises, and diastolic blood pressure
remains the same or rises slightly. In individuals with
hypertension, the exercise response may be exagger-
ated, or be blunted secondary to antihypertensive medi-
cations. After aerobic exercise, vasodilatation persists
short term and systolic blood pressure remains 25%
lower than the preexercise blood pressure for approxi-
mately 90 minutes(79). The mechanisms which may be
responsible for the long term effects of exercise on
lowering blood pressure are also not clearly identified,
but several hypotheses have been offered: 1 - de-
creased sympathetic nervous system activity, 2 - in-
creased levels of vasodilating prostaglandins, 3 - de-
creased levels of plasma renin activity, 4 - decreased
plasma volume and viscosity, and 5 - decreased insu-
lin resistance and decreased weight(73).
In several large population studies, physical fit-
ness has been associated with lower rates of cardio-
vascular disease, particularly of stroke and coronary
artery disease(80). This phenomenon has been observed
in diverse socioeconomic groups and different parts of
the world, including: middle-aged Finnish men(81), Bel-
gian factory workers(82), United States railroad work-
ers(83), and Harvard University graduates(84). In view
of the salubrious effect that exercise may have on
weight, insulin resistance and blood lipids, is appears
reasonable to include exercise as part of a compre-
hensive approach to treating hypertension.
5.4.2. Behavioural strategies for implementing an
exercise programme
The American College of Sports Medicine Guide-
lines recommend a full symptom limited exercise tol-
erance test for anyone over 45 years of age, or for
anyone over 35 years of age with a history of coro-
nary artery disease, smoking, obesity, hypertension, hy-
percholesterolemia, or a family history, and who wishes
to begin a new exercise programme(85). Although the
absolute risk is very low, individuals with coronary ar-
tery disease or associated risk factors are at risk for
sudden death with strenuous physical exercise(86). Pre-
paring a hypertensive patient for regular exercise re-
quires addressing psychological attitudes toward exer-
cise which can undermine success (Figure 7). Many
patients will suggest that they are “too busy” to exer-
cise. Similary, many patients will claim that their nor-
mal activities keep them so active that they get all the
exercise they need. Patients should be encouraged to
consider these objections in the context of their overall
values and goals. As with all behavioural interventions,
personal circumstances must be considered. There are
some patients who will need to learn the difference
between taking a two minute walk to the stock room
15 times a day and taking a 30 minute sustained walk.
There are other patients who will indicate that they
cannot exercise outside the home. The important points
to emphasize are that physical fitness should be fun,
should be personally relevant and also will pay great
dividends in lower cardiovascular risk.
To avoid untoward cardiac events, as well as
musculoskeletal injuries, patients should start slowly and
be taught important self-monitoring techniques.
Table III can serve as guidelines for prescribing
exercise in both healthy and sedentary adults(87).
Table III - Exercise prescriptions for health and
sedentary adults
1 - Exercise prescription for healthy adults
Frequency 3 to 5 x per week
Intensity 60 to 90% max HR
mod-heayy RPE
Time (Duration) 15 to 60 mimites (continuous)
Type (activity) Run, jog, walk, cycle, swim or
erdurance sports
2 - Exercise prescription for sedentary adults
Frequency Start with sessions every  other
day
Remain at 3 days per week or
progress to 5 days per week
Intensity 60 to 70 percent of maximal
heart rate or less
Light to moderate RPE
Gradually achieve target zone
70-85% of maximal heart rate
over weeks or months
Moderate RPE
Time (Duration) Start with 10-to 15-minute ses-
sions
Progress to 20- to 60-minute
sessions
Frequency Start with sessions every other
day
Remain at 3 days per week or
progress to 5 days per week
HR: heart rate;
RPE: rate of perceived exertion.
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and to adjust to changes in extrinsic demands. Yoga
and other techniques which elicit the relaxation response
are effective methods to teach body awareness. For
patients who are on beta-blocking medication, rating
of perceived exertion in fact may be the most effec-
tive way to measure exercise work load.
Moderate exercise yields about the same blood
pressure-lowering benefits as vigorous exercise and is
preferred, even for the active, healthy adult(89, 89). In-
struction in body awareness and rating of perceived
exertion (RPE)(90) are useful in teaching patients to
saty within their target zones, to monitor for symptoms
Figure 7 - Decision making matrix for exercise
ETT: exercise tolerance test; BP: blood pressure; Mod RPE: moderate rate of perceived exertion; ExRx: exercise prescrip-
tion; HR: heart rate.
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Patients should be encouraged to participate in
the development of their prescription. Individual dif-
ferences and preferences should be respected and ini-
tial level of fitness, including daily pattern of activity,
general health and age should factor into the exercise
prescription. Patients should identify the type of exer-
cise they most prefer, keeping in mind what is most
reasonable and feasile to maintain throughout the year.
Patients should make every attempt to incorporate
physical activity into their daily schedule in such a way
that it becomes a pleasure as opposed to work.
Modern technology has largely eliminated the
need for physical exertion at work and in our daily life.
Fifty years ago, factories and farms were supplied by
muscle power, today, however, few jobs require physi-
cal strength. The trade-off is that leisure has its price
and we have noted the increased risk for cardiovascu-
lar disease over this time period. For this reason, it
behooves us to look for ways in which to increase the
amount of physical activity we engage in during the
course of a day. Attention needs to be paid, however,
to cultural and societal influences.
In the United States, convenience is highly val-
ued while physical activity is devalued. In other cul-
tures, this is not the case. Personal and family beliefs
also should be considered. In some families, activity is
valued whereas in other families, it is not. Patients who
express a desire for structure or support tend to do
better exercising with a group. Adherence and out-
come improve with a significant other participants with
the patient in their exercise programme. As was the
case for sodium restriction, the institution of an exer-
cise programme for the treatment of hypertension has
multiple benefits. Individuals who begin regular exer-
cise have a tendency to lose weight and consequently
other cardiovascular risk factors are reduced. Another
important asset is that the institution of a regular exer-
cise programme can resuslt in a reduction of psycho-
logical stress. Regular exercise can reduce negative
psychological symptomatology thereby setting the stage
for more effective behavioural change.
5.5. Eliciting the relaxation response and stress
management
5.5.1. Scientific rationale for eliciting the relax-
ation response and stress management
Exposure to psychologically stressful situations
which cause anxiety can result in an acute elevation in
blood pressure. The relationship between emotional
arousal and a transient rise in blood pressure is well
established(91). The presumed mechanism for emotional
arousal is repeated elicitation of the “emergency re-
sponse” or “fight or flight response”(92,93). First de-
scribed by Walter B. Cannon, this response is charac-
terized by arousal of the sympathetic nervous system
(increased sympathetic nervous system activity) and
manifested by increased oxygen consumption, blood
pressure, heart rate, respiration rate and a 300 to 400
percent increase is skeletal muscle blood flow.
This relationship has led many clinicians and re-
searchers to hypothesize that repeated or prolonged
exposure to emotional arousal might result in chronic
hypertension(91). There is a substantial animal experi-
mental literature(94) and human observational litera-
ture(95) which supports this hypothesized interaction
between psychological stress and the pathogenesis of
essential hypertension. In fact, many patients believe
that psychological stress plays an important role in the
etiology of hypertension. Not surprisingly, these etio-
logical relationships have prompted attempts to use re-
laxation-response therapy and other stress manage-
ment approaches as intervention strategies for elevated
blood pressure.
The relaxation response is the physiologic coun-
terpart of the emergency response(96). It is character-
ized by decreased oxygen consumption, blood pres-
sure, heart and respiratory rates and a stabilization
of muscle blood flow(97). There are two common
steps in techniques that elicit the relaxation-response:
1 - the repetition of a word, sound, prayer or phrase
and 2 - the passive disregard of intruding thoughts
and a return to the repetition(98). Relaxation therapies
include procedures such as progressive muscular re-
laxation, yoga, diaphragmatic breathing, mental fo-
cusing, meditation, repetitive prayer, biofeedback and
autogenic training. All of these procedures may elicit
the relaxation response when appropriately ap-
plied(99).
In the discussion that follows, the terms relax-
ation therapy, relaxational therapies and relaxation train-
ing are all used for techniques that elicit the relaxation
response. The suffix “which elicit the relaxation re-
sponse” may be added as a suffix to these terms. The
use of this suffix is to remind the reader that irrespec-
tive of the specific procedure employed e.g. medita-
tion, autogenic training, yoga, or biofeedback, the com-
mon presumptive mechanism associated with the
lowered blood pressure from these relaxation thera-
pies is elicitation of the relaxation response.
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The understanding of this common response
has further import in that every culture has its own
techniques of eliciting the relaxation response, obvi-
ously, techniques can and should be chosen which re-
spect the cultural as well as personal beliefs of the
individual.
Stress management involves a wide variety of
psychological and behavioural procedures including
self-monitoring, time management techniques, cogni-
tive restructuring, as well as elicitation of the relax-
ation response.
Following initial positive reports in 1974 on the
effectiveness of yoga and other relaxation-response
approaches in the treatment of hypertension(100), clini-
cal studies proliferated with more than 60 outcome
reports in the literature(101). While the efficacy of these
interventions is still debated, there are positive reports
in the literature which strongly suggest that procedures
which elicit the relaxation response can have a clini-
cally significant effect on blood pressure and that they
can be an effective adjunctive treatment when used in
conjunction with pharmacotherapy(102-105). More re-
cently, some of these positive results have been criti-
cized on methodological grounds(101). Although a criti-
cal review is not possible here, an overview of the most
current conceptualizations concerning the relevance of
relaxation therapies and stress management for the
treatment of hypertension can be presented.
There are several fundamental rationales for
using relaxation techniques in hypertensive patients.
These involve the presumed relationship between es-
sential hypertension and arousal of the sympathetic
nervous system(106). If relaxation therapies and other
stress management interventions are hypothesized to
reduce sympathetic activity(107), then, it would be ex-
pected that psychological interventions would be most
effective for patients with evidence of higher arousal
of the sympathetic nervous system. There have been
conflicting reports concerning this relationship(108,109).
An indirect test of the sympathetic arousal hypothesis
can be made by examining the relationship between
anxiety levels and response to treatment(110), because
elevated sympathetic nervous system activity might be
expected to be associated with higher anxiety. Whereas
some studies report a positive association between
anxiety and response to treatment(110,111) other studies
report that lower levels of anxiety predicted better
treatment response(112,113).
Another rationale for the use of these therapies
is more recent and involves the concept of the reac-
tive or “white coat” hypertensive patient. There are
apparently a relative large number of patients who
carry the diagnosis of hypertension, but whose blood
pressure is elevated only during clinical evaluation by a
physician(114). The use of ambulatory monitors has al-
lowed the examination of this phenomenon and as many
as 20% of all diagnosed hypertensive patients exhibit
this effect(115). Since these episodic and situation spe-
cific elevations are most likely due to anxiety associated
with the medical evaluation, relaxation therapies and
other psychological interventions obviously are relevant.
A recent comprehensive review of the litera-
ture indicated that at present, no psychological vari-
able could discriminate responders to psychological treat-
ment from non-responders(116). Most researchers agree
that exposing hypertensive patients to relaxation train-
ing and stress management will result in reduced blood
pressures. However, the effects observed may be the
result of research designs which fail to accurately ac-
count for blood pressure variability(101). The positive
results reported may be due to the fact that at the on-
set of most studies, patients are more aroused, stimu-
lated and reactive to the measurement of blood pres-
sure. Hence, pretreatment to post-treatment reductions
would be expected to occur irrespective of the nature of
the interventions (pharmacologic/nonpharmacologic).
Indeed, there is a meaningful relationship between
the length of pre-treatment evaluations and the magni-
tude of intervention-mediated blood pressure reduc-
tions(101). Thus, relaxation therapies and stress-man-
agement therapies may act by achieving decreased
sympathetic nervous system arousal. If this be the case,
hypertensive patients should be exposed to those
therapies before pharmacologic therapy is initiated or
expanded.
In other words, the issue of blood pressure re-
activity to the measurement procedure itself is becom-
ing increasingly important. If the positive results of any
clinical trials (pharmacologic or nonpharmacologic) are
indeed the result of a progressive decrease in arousal
as the patients proceed in the study, then it may be
particularly important to acknowledge that for many
patients, relaxation and stress management may be a
very effective way to facilitate reduced arousal.
Clinicians must treat the blood pressures that they
observe. Pickering(117) has offered a schema for evalu-
ation of patients with elevations in blood pressure but
who may be exhibiting spurious elevations due to
exaggerated arousal. The schema is presented in
Figure 8.
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Despite the complexity and uncertain nature of
the research involving psychological variables in the
treatment of hypertension, the effect of psychological
arousal on blood pressure must be considered if only to
prevent misdiagnosis. To the extent that psychological
arousal is a component of a patient’s blood pressure
level, relaxation therapy in particular and stress man-
agement in general should be considered part of the
comprehensive intervention package.
Still another rationale for the use of relaxation
therapies and stress management in hypertension is the
effects of these interventions on other nonpharmaco-
logic treatment approaches. Nonpharmacologic inter-
ventions of any sort require behavioural change. Be-
havioural change is stressful(118). Relaxation and stress
management may very well facilitate the dietary and
exercise changes discussed above(119), since regular
use of relaxation therapy reduces negative psychologi-
cal symptoms of anxiety, depression and hostility in hy-
pertensive patients(105) and may make the prescribed
anti-hypertensive behavioural adjustments easier(119).
There is no consensus concerning the use of psy-
chological interventions such as relaxation therapies and
stress management in hypertensive patients. The Ca-
nadian Consensus Conference did not recommend that
people participate in such interventions to prevent hy-
pertension and considered it premature to recommend
that hypertensive patients use them therapeutically(9).
The most recent Joint National Committee in Treat-
ment of Hypertension(1) conclusion was equivocal. It
recommended that “all patients be introduced to some
type of psychological or behavioural therapy”, but also
indicated that “these promising methods have yet to be
subjected to rigorous clinical trial evaluation and should
not be considered as definitive treatment for patients
with high blood pressure”. However, despite this equivo-
cation, there was a continued recommendation to use
relaxation therapy and stress management for the treat-
ment of mild hypertension and as adjunctive therapy
for more severe hypertension(1).
Neither of these reports specifically addressed
the importance of these therapies as they relate to the
issue of sympathetic arousal and white coat hyperten-
sion nor do these reports comment on the facilitating
effect that these treatments may have on other nonp-
harmacologic interventions in reducing cardiovascular
risk profile. These latter two concerns coupled with
the suggestion of the JNC prompts us to recommend that
relaxation therapies and stress management continue to
be included in comprehensive treatment programmes.
According to this procedure, the patient is given
the opportunity to demonstrate that the pressure is char-
acteristically low under conditions of low arousal and
that the high values which prompted clinical concern
were due to the unusual circumstances associated with
the clinic visit. Home monitoring doesn’t necessarily
eliminate anxiety and arousal nor is it often economi-
cally feasible. Even the use of ambulatory monitoring
cannot completely overcome anxiety and arousal and
is a very expensive assessment procedure for routine
use. Therefore, reduced arousal during the clinic as-
sessment becomes an important behavioural goal for
many patients. White coat hypertensive patients not
only have clinic-related arousal as an issue, but appar-
ently, repeated clinic visits fail to result in a decrease.
For this category of patients, relaxation training directly
associated with clinic visits may be an important as-
pect of treatment(115).
Figure 8 - Evaluation of “resistant” hypertension by
ambulatory and home blood pressure (BP) monitoring.
From Pickering TG: Hypertension 11 (Suppl II): 11-96, 1988.
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5.5.2. Behavioural strategies for implementing re-
laxation therapy and stress management
No other intervention requires as much concern
for individuality of patient needs as do the psychologi-
cal therapies. To suggest that psychological interven-
tions can importantly impact on physiology triggers
many reactions. Some patients will enthusiastically en-
dorse the suggestion that stress may play some role in
their hypertension and that relaxation therapy and
stress management may help control it. Many patients
will also readily acknowledge the role that stress
plays in promoting smoking, overeating and lack of
exercise. For these patients, relaxation and stress
management can easily become an integral part of
treatment.
For other patients, due to personal perspective
or family and cultural influences, the suggestion that
stress may be a consideration in hypertension may
seem inappropriate, blaming, or even threatening.
For these patients, the rationale for elicitation of the
relaxation response and stress management must be
presented in a practical, non-threatening manner. It
should be recognized that for many patients the con-
cept of psychophysiology is new. Many are comfort-
able with the distinction between physical illnesses such
as hypertension and mental issues such as anxiety.
To suggest that they influence each other may be
seen as problematic by some and may be perceived
as blaming by others. In our experience however, tak-
ing the time to explain the interaction between thoughts,
feelings, emotions, behaviour and physiology is a cru-
cial first step and usually pays worthwhile dividends.
For those with suspected “white coat hyperten-
sion”, the stimuli associated with the measurement pro-
cedures cannot easily be eliminated. But repeated
measurements over time is a standard strategy used to
eliminate these anxiety-induced effects. Home blood
pressure monitoring provides useful clinical informa-
tion, and also allows the patient to feel a sense of part-
nership in their care while at the same time becoming
less sensitive to the procedure. Ambulatory monitoring
is another strategy which can be used to circumvent
the white coat effect. Furthermore, physician referral
for treatment to behavioural specialists is an option. In
this case, the nonpharmacologic treatment is more fo-
cused on the relaxation response and desensitization
to the measurement procedure itself and special atten-
tion can be given to the home blood pressures obtained
by the patient.
Stress management and the relaxation response
should be carefully introduced in a manner which ac-
knowledges the biopsychosocial model and its applica-
tion to the etiology of hypertension (Figures 9 and 10).
Emphasis should be placed on establishing a biopsy-
chosocial or psychophysiologic link between stress,
sympathetic arousal, increased anxiety and elevations
in blood pressure. The relationship between stress and
adverse lifestyle behaviours (stress-disinhibition) should
be explained. After establishing these important links
and once patients are comfortable with the concept of
relaxation training and stress management, a formal
programme can be instituted.
Because stress causes both psychological dis-
tress and physiological arousal a phenomenon called
the “stress-disinhibition” effect has been described(120).
Upon exposure to environmental demands which are
perceived as stressful, previously inhibited behaviour
patterns are likely to emerge. Hence, a patient’s ability
to exercise, elicit the relaxation response daily, restrict
salt intake or reduce calories in general may be com-
promised by stress exposure. Relaxation therapies and
stress management procedures directly address this
issue and may therefore enhance the effectiveness of
other behavioural interventions. This issue will be dis-
cussed in more detail when the concept of high risk
situations is presented.
We recommend including four basic components
in a formal programme. These are: 1 - systematic self-
monitoring of circumstances which are perceived as
stressful; 2 - a systematic attempt to alter the environ-
mental demands so that stressful circumstances are
less likely to occur; 3 - a formal relaxation training
programme in which the relaxation response can be
elicited daily in order to reduce psychological and physi-
ological arousal and; 4 -  exposure to cognitive restruc-
turing exercises.
In addition to eliciting the relaxation response on
a regular basis, it is also useful to instruct patients to
utilize the relaxation response as an immediate stress
reliever in specific situations Figure 9. For example,
when they have their blood pressure measured, en-
counter a traffic jam, or engage in a particularly diffi-
cult conversation they can stop, take a few deep breaths
and thus bring forth the physiology of the relaxation
response, mitigating some of the acute psychophysio-
logic effects of stress.
The practicing clinician can accomplish a great
deal in a short office visit (Figure 10). Begin by simply
asking patients if they are stressed. Then ask them
to rate the amount of stress in their life on a scale of
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Figure 9 - Decision making matrix for the relaxation response
RX: Prescription;
PMR: progressive muscular relaxation.
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Figure 10 - Decision making matrix for managing stress
BP: blood pressure.
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1 to 10. If they indicate that they are stressed, ask
them to rate the amount of stress that they experience
at home, work, socially, interpersonally and in regards
to their health on a scale of 1 to 10. Ask them if they
think that they are coping with the stress in their life.
Research has shown that if the patient perceives them-
selves as being stressed, they are. Simply by asking
about the amount of stress in their life, the clinician is
educating the patient to the fact that stress can have
an impact on a patient’s health. The clinician is also cre-
ating the opportunity to allow the patient to discuss their
concerns and to be empathetic. This in and of itself
can be very helpful in treating stress. If the patient is
stressed the clinician might then ask the patient to iden-
tify the pattern of stress which they are experiencing.
Is the stress they are experiencing acute-in response
to a specific situation-or is it in a more pervasive pat-
tern which is impacting on their daily life? This will
provide the clinician whith the information needed to
determine whether they should work with the patient
one-on-one or refer them to a formalized programme.
For those patients who are in the precontempla-
tion and contemplation stage, it is important to acknowl-
edge their stress and to establish the connection be-
tween stress and adverse psychophysiologic effects.
Engender a positive attitude so that the patient feels
that they can be successful in altering their pattern of
stress. In those patients who are ready to change, the
clinician should choose an approach to managing stress
wich respects the individuals interests, beliefs and
lifestyle. Patients who are concrete and who have dif-
ficulty acknowledging the psychophysiologic compo-
nent to stress may do best, initially, to approach stress
management through a programme of exercise, reduc-
tion in caffeine, alcohol and cigarettes. Once they have
begun, the clinician can then introduce the notion that
these approaches are likely most effective when used
in conjunction with regular elicitation of the relaxation
response. Patients can then be instructed in a variety
of techniques which can elicit the relaxation response.
Basic instruction can be given in the of f ice and the
patient can be sent home with written instruction and a
tape of relaxation-response exercises. Other patients
will do best initially to begin with cognitive approaches
and eliciting the relaxation response, then to address
additional components including exercise and dietary
modification.
Simple techniques which elicit the relaxation re-
sponse such as progressive muscle relaxation, diaphrag-
matic breathing and meditation can be easily learned
in an office visit. Techniques which may require more
supervision a-nd follow-up such as yoga or autogenic
training may be best addressed in a group or struc-
tured format. It has been our experience with hyper-
tensive patients that it is more effective to start by us-
ing concrete technique such as progressive muscle
relaxation and diaphragmatic breathing although indi-
vidual differences should be acknowledged.
Table IV shows the basic prescriptive compo-
nents for eliciting the relaxation response:
Cognitive behavioural approaches to stress man-
agement stem from the viewpoint that what we think
influences our emotions, which in turn influence our
physiology, and ultimately our health. Although it is dif-
ficult to carry out a systematic approach to cognitive
restructuring in the confines of a short office visit, the
clinician can endorse the principles of cognitive restruc-
turing and encourage patients to participate either in a
self-instructional programme or a group which addresses
this therapeutic approach. Encourage patients through-
out the process of making changes in stress manage-
ment. Patients often want immediate sucess. If pa-
tients appear upset that stress is still a problem,
encourage them to think of stress management as a
process rather than an immediate cure. Even if pa-
Table IV - Relaxation response prescription
THE BASICS
• passive mental attitude to intruding thoughts;
• repetition of a simple mental stimulus such as
a word, sound, prayer, phrase or muscular activ-
ity.
GENERAL PRESCRIPTION
• practice once a day for 20 minutes; alternative
would be twice a day fot 10 minutes each;
• do it in the same place every day;
• do it first thing in the morning;
• take the phone off the hook;
• tell the family, secretary, etc not to bother you;
• don’t use the alarm clock; set a watch in front of
you; alternatively, put a pillow over an alarm
clock so it rings softly;
• don’t do it right after a large meal;
• if you are uncomfortable, make yourself com-
fortable.
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tients have not totally mastered the stresses in their
life, encourage them in whatever changes that they
have made. As previously indicated, these relaxation
and stress management components are most effec-
tively used when they are embedded within a com-
prehensive intervention programme addressing other
cardiovascular risk factors and employing other non-
pharmacologic interventions.
5.6. Tobacco
5.6.1. Scientific rationale
There have been no definitive studies indicating
that cigarette smoking causes hypertension. Smoking
does induce an acute pressor effect, but the body ha-
bituates to this effect so that chronic smoking is not
associated with elevations in blood pressure or in-
creased risk of developing hypertension(121). Nonethe-
less, those who have hypertension and who smoke sig-
nificantly increase their risk for coronary artery disease,
myocardial infarction, sudden death and stroke(122). In
addition, individuals with hypertension who smoke have
an increased incidence of malignant hypertension and
subarachnoid bleeding(123). Smoking also decreases the
effectiveness of selected antihypertensive medica-
tions(124).
As noted, the cardiovascular risks associated
with hypertension coupled with smoking are high. An
individual with hypertension who smokes has an in-
creased risk of myocardial infarction and stroke three
to five times greater than a hypertensive patient who
does not smoke. This data led the Joint National Com-
mittee to state that, “the benefits of tobacco avoidance
have been proven conclusively, and smoking cessation
is strongly recommended. A key component of every
therapeutic regime for hypertension should include
counseling to help patients stop smoking”(1).
The direct relationship between smoking and
blood pressure is less important than the relationship
among multiple cardiovascular risk factors. The need
to engineer smoking cessation as part of a nonphar-
macological treatment programme in hypertension high-
lights the need to consider the patient from a multidi-
mensional perspective. In addition to smoking being
one of several risk factors, the behaviours associated
with these risk factors are interrelated.
5.6.2. Behavioural strategies for smoking cessation
Smoking cessation approaches for hypertensive
patients are no different than other smoking cessation
programmes. In some cultures, there isincreasing
social pressure to stop smoking although commercial
advertisements persistently encourage it on the other
hand, there are cultures in which smoking is consid-
ered quite appropriate. The approach recommended
to help patients to stop smoking should be made with
these cultural differences in mind. All patients who are
currently smoking should be advised to stop. It is im-
portant for the clinician to express their concern and
strong conviction that it will benefit the patient’s over-
all health and prevent premature stroke and cardiovas-
cular disease. United States Surgeon General C. Everett
Koop(125) felt strongly enough to state that the single
most important thing that one can do for their health is
to stop smoking. The clinician is paramount in motivat-
ing the patient to stop smoking.
Once you have determined the patient’s moti-
vation, you can create the specific plan (Figure 11). If
patients are not yet ready, it is important to give infor-
mation, encourage patients to stop smoking and en-
gender the belief that they can be successful at smok-
ing cessation. It is also important to follow up on smoking
status on each subsequent visit. For the patient who is
motivated and ready to change, the first step is to take
a complete smoking history. Within this history it is im-
portant to get an accurate picture of how addicted they
are to nicotine as well to get a perspective on the
biopsychosocial factors influencing their smoking pat-
tern. Establish realistic expectations and a specific date
to quit. Encourage the patient to complete a smoking
self-assessment and begin to prepare for nicotine
withdrawal. Nicotine is considered to be an addictive
drug. It has recently been reported to be as addictive
as either heroin and cocaine(126). The physical symp-
toms of nicotine addiction subside in one to three weeks
but psychosocial addiction lasts much longer. Patients
should be prepared for the withdrawal symptoms
including: cravings, anxiety, irritability, headache,
drowsiness, restlessness, GI symptoms and difficulty
concentrating. Table V presents some useful inter-
ventions to deal with the symptoms of nicotine with-
drawal(127).
Nicotine chewing gum can be used as a short
term weaning mechanism but should not be used as a
long term substitute. The average smoker will chew
six to ten pieces per day, begin to drecrease this amount
after two to three months and completely discontinue
the chewing gum by six months. It is also useful to
switch to a low tar, low nicotine brand of cigarette and/
or to begin switching brands. Tapering the number of
cigarettes smoked each day is another helpful wean-
ing technique.
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skills, including distraction, delay, not giving in to the
urge, deep breathing, escape, positive self-statements,
cognitive restructuring, and recommitting to the ben-
efits of quitting.
Patients should practice coping skills for high risk
situations such as negative affect, sudden stress, bore-
dom, eating/drinking, and social situations. They need
to have a variety of behaviour and cognitive coping
Figure 11 - Decision making matrix for smoking cessation
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Table V - Approach to symptoms of nicotine withdrawal
Symptom Prescription
Anxiety irritability Diaphragmatic breathing
Relaxation techniques 6-8 hours sleep
Decrease of eliminate stimulants
Exercise (eg walking)
Avoid unnecessary stress
Nicotine gum
Accept as normal
Talk with support person
Headaches Avoid caffeine
Sleep disturbance Deep breathing / relaxation, especially
before retiring
Avoid unnecessary stress
Regular exercise
Increased appetite Increased water intake
Gnawing stomach Low-calorie snack
Nausea Noncalorie oral substitutes
Constipation Increase fluids
High fiber diet
Fatigue Maintain regular work / relaxation / sleep
Drowsiness schedule
Decreased Aerobic exercise
concentration Decrease or eliminate depressants
Break from work and do light calisthenics
Change activity
Do not start new projects
Cough Accept as natural part of nicotine
 withdrawal
From McKool K. Facilitating Smoking Cessation. Journal of Cardiovascular
Nursing. 1987; 1: 36(127).
Exercise and eliciting the relaxation response
have been found to be particularly helpful in dealing
with the symptoms of nicotine withdrawal. Again, as is
the case for weight loss, referral to a multi-factorial,
nonpharmacologic treatment programme or a smoking
cessation programme may be useful.
5.7. Other dietary considerations
5.7.1. Potassium supplementation
Recently it has been suggested that the addition
of potassium, calcium and magnesium to the diet of
the hypertensive patient might be ben-
eficial. There is a growing interest in
potassium supplementation as a treatment
modality for lowering blood pressure(128).
Several large population studies have sug-
gested that dietary potassium is negatively
associated with blood pressure(129, 130) and
that the sodium/potassium ratio is posi-
tively associated with elevated blood
pressure(131). Some studies have suggest-
ed that the 20th century diet of processed
and fast food which is high in sodium and
low in potassium is responsible for these
findings. Diets high in potassium have
been associated with a reduction in
stroke-associated mortality with one
study reporting a 40% reduction in stroke
with the addition of 10 mmol/day of po-
tassium(132, 133). A similar protective ef-
fect was noted in Japanese men living in
Honolulu(134). Increases in potassium in-
take (8OmEq or 3-4 g/day) have been
shown to lower systolic and diastolic
blood pressure by 10 mmHg(135). This in-
verse effect of potassium to blood pres-
sure was noted to be greater in blacks(135).
The mechanisms by which potas-
sium may lower blood pressure and con-
tribute to reduction in risk are not pre-
cisely understood. Several hypotheses
have evolved including: potassium pro-
duces a natriuretic effect thereby de-
creasing extracelular volume and blood
pressure(136), potassium alters the activ-
ity of the renin/angiotensin system, po-
tassium relaxes smooth blood vessels
thereby decreasing peripheral vascular
resistance. There is some evidence that increased po-
tassium may modify central and peripheral neural
mechanisms that regulate blood pressure(36).
Specific recommendations have been made by
the Canadian Consensus Group(9) and the Joint Na-
tional Committee(1) to increase potassium through
simple dietary modification along with decreased di-
etary sodium intake. Caution should be exercised in
patients with abnormal renal function or on potassium
sparing diuretics. It has also been suggested that modi-
fication of the diet should concentrate on reducing the
amount of processed and fast food since they tend to
be high in sodium and low in potassium. Kaplan warns
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of the dangers inherent in using supplements to meet
the recommendation to increase potassium. Although
this may sound easier, he notes that they are costly
and potentially hazardous and should be reserved for
diuretic-induced hypokalemia(10).
5.7.2. Calcium, Magnesium, Zinc, and Lead
The evidence regarding the blood pressure low-
ering effect of these cations or their impact on the over-
all cardiovascular risk profile is meager and mixed. The
Joint National Committee(1), Canadian Consensus
Panel(9), and World Health Organization(6) did not issue
any recommendations regarding these cations.
5.7.3. Dietary fats
There is evidence in population studies that di-
etary fats influence blood pressure. Specifically, de-
creased consumption of fat and an increased polyun-
saturated/saturated (P/S) ratio decreases blood
pressure(137). However the evidence from clinical tri-
als is conflicting and controversial, several mechanisms
have been postulated to explain the effect of dietary
fat on lowering blood pressure: an influence on renal
excretory function, altered prostagladin metabolism,
and alterations in the composition of cell mem-
branes(138). The results of clinical studies, however, have
not been definitive.
The general recommendation issued by the Joint
National Committee(1), Canadian Consensus Report(9)
and the World Health Organization(6) concludes that
the evidence is inadequate to recommend decreased
dietary intake of fat and increased P/S ratio to lower
blood pressure. They did, however, agree that decreas-
ing total dietary fat is important as a means to decrease
cholesterol, decrease weight and impact favourably on
the overall cardiovascular risk profile. The goal is to
reduce cholesterol to less than 200 mg/dl, reduce LDL
to less than 140 mg/dl, increase HDL to greater than
40 mg/dl and reduce the total cholesterol to HDL ratio
in females to less than 3.5 and in males to less than 4.5.
5.7.4. Fish oil
Several population studies have shown an
association between increased consumption of fish
(particularly cold water fish) and decreased incidence
of cardiovascular disease. Cold water fish are rich in
omega-3 fatty acids, which have been widely reported
to: decrease platelet aggregation, reduce vascular oc-
clusive disease, and decrease blood pressure. The pre-
sumptive mechanism for these effects is the production
of endogenous eiconsanoids, mainly prostaglandins(139).
It is the consensus(1,6,8,9) that the benefits of fish
oil supplementation have not been clearly demonstrated,
and that there was a significant risk of bleeding with
these supplements. It has therefore been recom-
mended that individuals increase their consumption
of fish (particularly oily fish), but not use fish oil
supplements(1,9).
5.7.5. Caffeine
Decreasing daily caffeine intake is popularly
believed to reduce blood pressure. It has been demon-
strated that ingestion of caffeine can have an acute pres-
sor effect, elevating blood pressure five to 15 mmhg
after two three cups (250 mgm) of coffee. The blood
pressure can then remain elevated for as long as
two hours. However, chronic coffee ingestion of six
cups/day (500 mgm) over four weeks was not found
to be associated with sustained increased in blood pres-
sure(140). Additionally, there are no population studies
that show a positive association with coffee consump-
tion and prevalence of hypertension(141).
Therefore reduction of caffeine is not specifi-
cally recommended to lower blood pressure or impact
on the overall cardiovascular risk profile(1,9).
5.8. Combined therapies
Primary or essential hypertension is not a uni-
tary disorder. Therefore it is not surprising that there is
uncertainty about the efficacy of each nonpharmaco-
logic intervention. It may also explain why monothera-
py may not be as a combined, or multifactorial approach.
Understanding the etiology and treatment of hyperten-
sion requires an appreciation of the complexity of the
circulatory system with overlapping control mechanisms,
intrinsic and extrinsic, and influenced by the central
nervous system which is in turn influenced by the
patient’s perceptions and cognitions. In addition, the
goal of hypertension treatment is twofold: first to lower
blood pressure and secondly to favourably impact on
the overall cardiovascular risk profile.
There have been studies which combine thera-
pies in a multifactorial treatment approach even though
these studies have methodological caveats. It has been
demonstrated that patients could successfully lower
blood pressure through a variety of nonpharmacologic
interventions and combinations of interventions, and that
they could successfully maintain these reductions in
blood pressure over time(142-144). Some of these same
studies demonstrated a concomitant reduction in anti-
hypertensive medications.
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Two large recent trials have viewed the ef-
fectiveness of combining nonpharmacologic and
pharmacologic therapies. In the Trial of Antihyper-
tensive Intervention and Management (TAIM), 878
patients were randomized to one of three antihyper-
tensive drugs; chlorthalidone, atenolol, placebo and
one of three antihypertensive diets; reduced calo-
rie, reduced sodium/increased potassium, usual. Af-
ter six months, those randomized to chlorthalidone or
atenolol plus reduced calorie diet – and who had lost
a mean of 10 pounds – had the greatest reduc-
tion in blood pressure. In addition, weight reduction
was an independent predictor of pressure reduc-
tion(145,146).
The Treatment of Mild Hypertension Study
(TOMHS) studied 468 patients with mild hypertension.
They were first prescribed a programme of weight re-
duction, sodium reduction, alcohol reduction, and thera-
peutic exercise, and were then placed on either pla-
cebo or one of five antihypertensive medications. After
eighteen months, both the placebo plus nonpharmaco-
logic group and the active drug plus nonpharmacologic
group had achieved statistically and clinically signifi-
cant reductions in blood pressure. The active drug plus
nonpharmacologic group achieved the greatest reduc-
tions(147).
The Canadian Consensus Panel(9), the Joint Na-
tional Committee on Detection, Evaluation and Treat-
ment of Hypertension(1), the World Health Organiza-
tion(6), and the British Hypertension Working Party(8),
have stated that hypertension is only one factor in the
genesis of cardiovascular disease, and that it should be
seen in the context of a multifaceted approach to the
prevention and treatment of cardiovascular disease.
Therefore, it is logical to approach treatment in this
manner.
We recommend a comprehensive nonpharma-
cologic treatment programme as being more effective
than unidimensional interventions for several reasons:
1 - there are few precise diagnostic methodologies to
identify specific nonpharmacologic interventions; 2 -
the goal is to both lower blood pressure and reduce
overall cardiovascular risk; and 3 - the interventions
work synergistically.
The 13-session programme entitled the Cardiac
Risk Reduction Clinic developed by the authors and
their colleagues at the New England Deaconess Hos-
pital, incorporates the multifactorial components of
nonpharmacologic treatment for hypertension described
throughout this paper.
6. CARDIAC RISK REDUCTION CLINIC
The philosophy of this clinic is to provide a com-
prehensive, integrated, biopsychosocial approach to the
care of the patient needing to modify adverse cardio-
vascular risk factors and attain better control over their
blood pressure. We emphasize that the clinic is inter-
disciplinary staffed by nurses, physicians, psychologists,
nutritionists and exercise therapists. The specific aims
of the Cardiac Risk Reduction Clinic are to:
• reduce the cardiovascular risk profile, specifically to:
– lower elevated blood pressure,
– normalize serum lipids,
– eliminate smoking,
– reduce sodium, fat, and calories if appropriate,
– reduce alcohol if appropriate,
– increase exercise capacity,
– reduce elevated stress levels,
– stabilize glucose tolerance.
• demystify care,
• engender a positivie attitude,
• promote self-care,
• empower patients to participate in their care, and
• teach patients to elicit the relaxation response.
Emphasis is placed on self-assessment, goal set-
ting, selfmonitoring skills, self-care strategies and a
variety of coping and relapse prevention skills. Each
clinic session is designed to model and value the goals
we have described. We incorporate therapeutic exer-
cise, body awareness, affirmations, elicitation of the
relaxation response and a discussion series into each
session. Patients are asked to monitor and record their
own symptoms and progress on diary cards and are
encouraged to participate in their treatment planning.
All aspects of the curriculum – therapeutic ex-
ercise, body awareness, training in the elicitation of the
relaxation response, affirmations, nutrition education and
stress management are designed to emphasize:
• Knowledge
– that information necessary to understanding the bi-
opsychosocial dimensions fo interventions, the risks
attendant in not treating hypertension and the es-
sentials of self-care.
• Skills
– strategies for change.
– self-monitoring skills including:
♦ symptom monitoring,
♦ home blood pressure measurement,
♦ home glucose monitoring,
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♦ body awareness,
♦ rating of perceived exertion,
♦ stress warning signals weight,
♦ heart rate monitoring,
♦ eliciting the relaxation response,
♦ therapeutic exercise,
♦ expanded coping styles,
♦ stress management,
♦ relapse prevention.
• Attitude
– utilizing cognitive restructuring and the relaxation
response to promote an attitude conductive to
mind/body health.
Family and/or significant others are encouraged
to participate as a way of supporting the patient in
making these changes.
Prior to entering the programme each patient is
evaluated individually to confirm the diagnosis fo hy-
pertension, rule out secondary causes for the diagno-
sis, and ascertain the patients readiness and motiva-
tion for behavioural change. At this intake evaluation
patients are invited to become participants in their care
planning. At this time, the patient’s medication use is
discussed and a strategy for drug titration is consid-
ered. Throughout the programme, the weekly blood
pressure of medicated patients should be evaluated.
Consistent reductions can prompt reduced medication
requirements. Since patients are frequently seen in the
programme, this represents a particularly good time to
evaluate medication use.
Following the intake evaluation, in preparation
for the first clinic session patients;
• view an instructional videotape on a simple technique
to elicit the relaxation response;
• listen to an audiotape each day for 20 minutes which
guides them in a simple breath focused technique to
elicit the relaxation response;
• read Chapters 2, 4, and 5 in a manual entitled The
Wellness Book(148).
SESSION 1
Introduction to the clinic
• staff introductions who we are, what we expect from
them, what they can expect from us
• patient introductions – who they are, what motivated
them to come, what they expect from us
• general information and expectations
Data collection
• blood pressure, heart rate, weight, blood sugar
Goal setting lecture
• With an emphasis on: value clarification, life meaning
and purpose, long range goals, short term strategies,
strengths/weaknesses, social support and monitoring
parameters.
In preparation for Session 2
• read Chapters 1 and 3 in The Wellness Book
• complete the values clarification exercise
• complete the self-portrait
• begin goal sheet
• purchase home blood pressure kit
• complete daily diary
SESSION 2
Individual Prescription session
• review of medical treatment
• data collection
• set specific goals and agree upon strategies and plan
• exercise prescription
• nutrition prescription
• relaxation response/body awareness prescription
• answer specific questions
In preparation for Session 3
• read Chapters 7 and 22 in The Wellness Book
• complete daily diary
• purchase home blood pressure monitoring kit and bring
to the next session
SESSION 3
Self-monitoring of blood pressure
Simple instruction in home blood pressure monitoring
and recording.
Exercise lecture, with an emphasis on;
• principles of therapeutic exercise
• body awareness
• cues for perceived exertion
• self-monitoring of symptoms including:
– angina
– hyper/hypoglycemia
– hyper/hypotension
– musculoskeletal
– snacks/insulin/exercise
• healthy pleasures – exercise for fun
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In preparation for Session 4
• read chapters 8 and 9 in The Wellness Book
• complete three day diet recall
• complete daily diary
SESSION 4
The remaining sessions (4 throught 13) follow the fol-
lowing format:
• data collection (10 minutes)
• warn-up (5 minutes)
• therapeutic exercise (30 minutes)
• cool-down/body awareness (10 minutes)
• relaxation response (15 minutes)
• discussion series (50 minutes) – topics change each
week
Discussion topic
Heart Healthy Nutrition with an emphasis on low so-
dium;
• 2,000 mg sodium food plan
• label reading
• food preparation
• menu selection
• behavioural factors
In preparation for session 5
• read Chapter 23 in The Wellness Book
• complete three day diet recall
• complete daily diary
SESSION 5
Therapeutic exercise/relaxation response
Discussion topic
Heart healthy nutrition, reducing calories and cho-
lesterol including:
• food plan less than 20 - 30% of calories from fat
• instruct in fat gram counting
• label reading
• food preparation
• menu selection
• behavioural factors/food choices
In preparation for Session 6
• read Chapter 21 in The Wellness Book
• complete risk factor checklist
• complete daily diary
SESSION 6
Therapeutic exercise/relaxation response
Discussion topic
The pathophysiology of cardiovascular risk factors spe-
cifically:
hypertension, dyslipidemia, and diabetes
• Biopsychosocial model for cardiovascular disease
with emphasis on antecedent factors and synergy of
factors.
In preparation for Session 7
• review Chapter 6 in The Wellness Book
• complete assessment for relaxation response
• complete weekly diary
• complete mid-programme evaluation of goals
SESSION 7
Discussion topic
Midway evaluation of progress toward goals
• reassess goals
• self measure of progress toward stated goals
• reconfirm commitment
• adjust goals as necessary
Hatha Yoga Exercises
• Developing body awareness, muscle stretching, joint
mobility and a method for aerobic cool-down
• Eliciting the relaxation response
In preparation for Session 8
• complete weekly diary
• read Chapter 10 in The Wellness Book
SESSION 8
Discussion topic
Stress physiology; cardiovascular reactivity to physi-
cal and emotional stress.
• The relationship of stress, sympathetic arousal, and
elevations in blood pressure,
• general psychophysiological reactions to stress
• strategies to reduce stress – relaxation response, ex-
ercise, cognitive, and behavioural
• the use of minis to alleviate acute stress
In preparation for Session 9
• complete weekly diary
• complete biodots exercise
• read Chapters 11 and 12 in The Wellness Book
• complete irrational beliefs inventory
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SESSION 9
Therapeutic exercise/relaxation response
Discussion topic
Cognitive restructuring: automatic thoughts, irrational
beliefs and distorted thinking styles.
In preparation for session 10
• complete weekly diary
• read chapters 13 and 14 in The Wellness Book
• complete “challenging stress and winning” worksheet
SESSION 10
Therapeutic exercise/relaxation response
Discussion topic
Coping and problem identification
In preparation for Session 11
• complete weekly diary
• complete anger expression scale
SESSION 11
Therapeutic exercise/relaxation response
Discussion topic
Coronary prone behaviour pattern: how thoughts, feel-
ings and emotions affect cardiovascular arousal and
health.
In preparation for Session 12
• complete weekly diary
• read Chapters 15 and 24
• confirm follow-up appointment
• make appointment for blood-work
• complete post-programme evaluation of goals, ques-
tionnaires, and self-portrait
• prepare a favourite heart healthy snack to bring to
the 12th session
SESSION 12
Therapeutic exercise/relaxation response
Discussion topic
Humor as a coping tool and relapse prevention
Programme conclusion
• general review of progress
• programme evaluation form
• collect post-programme evaluation of goals, question-
naires and self-portrait
• confirm post programmes lab work
• confirm follow-up appointment
• congratulations to one and all
In preparation for the follow-up visit;
• complete programme evaluation
• complete post-programme evaluation of goals, ques-
tionnaires and self-portrait
• complete blood work at least three days prior to fol-
low-up appointment
FOLLOW-UP SESSION (SESSION 13)
One hour individual session
• individual review of progress toward goals
• medical update
• sub-max exercise tolerance test (ETT) for measur-
ing exercise conditioning and upgrading exercise pre-
scription
• Written plan for maintaining health gains and prevent-
ing relapse
• medication consideration
STUART EM; FRIEDMAN R & BENSON H. Promoção de intervenções não-farmacológicas para  tratar hipertensão
arterial. Medicina, Ribeirão Preto, 31: 106-143, jan./march 1998.
RESUMO: Na primeira parte desta revisão, discutem-se a definição, prevalência, evolução
histórica e os princípios gerais do tratamento não-farmacológico da hipertensão arterial. Em se-
guida, apresenta-se a base principal e as estratégias comportamentais para redução da
obesidade, da ingestão de sal e de bebidas alcoólicas, do sedentarismo, do estresse emocional,
e do uso do fumo. Na parte final, discute-se o papel de outros fatores dietéticos, (das terapias
combinadas e, particularmente, como elas podem ser integradas em uma abordagem multidisci-
plinar do paciente hipertenso.
UNITERMOS: Hipertensão. Tratamento Não Farmacológico. Terapia Combinada.
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